Interaction of Carbamazepine with Herbs, Dietary Supplements, and Food: A Systematic Review

Fong, Sophia Yui Kau; Gao, Qiong; Zuo, Zhong

doi:https://doi.org/10.1155/2013/898261

Evidence-Based Complementary and Alternative Medicine

On this page

Abstract Background Materials and Methods Results Discussion Conclusion References Copyright Related Articles

Special Issue

Herb-Drug Interactions: Systematic Review, Mechanisms, and Therapies

View this Special Issue

Review Article | Open Access

Volume 2013 | Article ID 898261 | https://doi.org/10.1155/2013/898261

Interaction of Carbamazepine with Herbs, Dietary Supplements, and Food: A Systematic Review

Sophia Yui Kau Fong,¹Qiong Gao,¹and Zhong Zuo¹

Academic Editor: William C. S. Cho

Received26 Mar 2013

Accepted17 Jul 2013

Published19 Aug 2013

Abstract

Background. Carbamazepine (CBZ) is a first-line antiepileptic drug which may be prone to drug interactions. Systematic review of herb- and food-drug interactions on CBZ is warranted to provide guidance for medical professionals when prescribing CBZ. Method. A systematic review was conducted on six English databases and four Chinese databases. Results. 196 out of 3179 articles fulfilled inclusion criteria, of which 74 articles were reviewed and 33 herbal products/dietary supplement/food interacting with CBZ were identified. No fatal or severe interactions were documented. The majority of the interactions were pharmacokinetic-based (80%). Traditional Chinese medicine accounted for most of the interactions (), followed by food (), dietary supplements (), and other herbs/botanicals (). Coadministration of 11 and 12 of the studied herbal products/dietary supplement/food significantly decreased or increased the plasma concentrations of CBZ. Regarding pharmacodynamic interaction, Xiao-yao-san, melatonin, and alcohol increased the side effects of CBZ while caffeine lowered the antiepileptic efficacy of CBZ. Conclusion. This review provides a comprehensive summary of the documented interactions between CBZ and herbal products/food/dietary supplements which assists healthcare professionals to identify potential herb-drug and food-drug interactions, thereby preventing potential adverse events and improving patients’ therapeutic outcomes when prescribing CBZ.

1. Background

Introduced in 1960s, carbamazepine (CBZ) remains as one of the most commonly prescribed antiepileptic drugs worldwide and has established efficacy for the treatment of partial seizures, generalized tonic-clonic seizures, trigeminal neuralgia, and bipolar disorders [1–6]. Despite its clinical popularity, CBZ possesses several pharmacokinetic properties which make it prone to interaction with coadministered substances, including drugs, herbal products, and food [7]. CBZ is a potent inducer of CYP450 system and is subject to autoinduction. Its metabolism is exclusively hepatic and catalyzed by various enzymes including CYPs, UGTs, and SULTs [8]. CYP3A4 is the most important enzyme involved in the metabolism of CBZ as it leads to the formation of the active metabolite CBZ 10,11-epoxide, which appears to contribute to the toxicity and efficacy of CBZ [9, 10]. Furthermore, CBZ has a considerably narrow therapeutic index of 2-3 while there is a wide interindividual variation in tolerable doses and blood levels, making therapeutic drug monitoring and slow titration necessary [11, 12]. Many side effects associated with CBZ are concentration-related. Nausea, vertigo, dizziness, and blurred vision are examples of CBZ adverse effects which mostly are mild, transient, and reversible if the dosage is reduced or if initiation of treatment is gradual [13]. Signs of toxicity generally occur at plasma CBZ concentrations in excess of 10 to 12 mg/L, with diplopia, nystagmus, and aplastic anemia being the most characteristic ones [11]. Fatal cases of CBZ overdose were also recorded where patients were manifested with cardiac arrhythmias, abnormal movements, and seizures [14]. The occurrence of CBZ overdose is usually accidental, and in most times it is secondary to the coadministration of other substances [15–20].

Since antiepileptic regimens are normally given on a long-term basis, the opportunity of a clinical significant interaction between CBZ and coadministered substances is considerably high. Herbal medicines, dietary supplements, and food may interact with CBZ pharmacokinetically and/or pharmacodynamically which leads to potential clinical consequences. One of the contributing factors towards increasing incidence of herb-drug interaction is the increased popularity of herbal medicines [21]. According to pharmacoepidemiologic surveys, the percentage of epileptic patients concurrently taking complementary and alternative medicines and antiepileptic drugs is considerably high in both developed and developing regions: United States (39%), Cambodia (36%), United Kingdom (34%), Taiwan (16%), Nigeria, (15%) and India (12%), while more than 60% of them did not inform their physicians [22–27]. In China, integrated medicine is a common practice where Western and traditional Chinese medicines are prescribed concurrently for the treatment of epilepsy [28]. Therefore, the opportunity of patients taking CBZ with herbal/dietary supplements is high, and it is necessary to address the safety issues of such combinational use.

When making clinical decisions on the use of herbal or dietary supplements, the review article is one of the major information sources for healthcare professionals [29]. In view of this, we tried to identify existing review articles that (1) summarized all the reports and studies on the pharmacokinetic and pharmacodynamic interactions of CBZ with herbs, dietary supplements, and food and (2) provided recommendations on their combinational use. It was found that there is a lack of well-conducted systematic review on CBZ and its herb, food, and dietary supplement interactions. The searching strategy adopted by these reviews is not comprehensive enough to identify all the relevant articles. Most of these reviews use general terms such as “herb-drug interaction” as searching keywords and do not focus on one particular drug (e.g., CBZ) [30–33]. This nondrug-specific searching method may result in missing CBZ-relevant papers if the paper does not contain the phrase of “herb-drug interaction”. Besides, there is no single review that covers the interactions between CBZ and all the three aspects of herb, food, and dietary supplement. A systematic review is warranted to provide guidance for healthcare professions when prescribing and monitoring patients taking CBZ. From the review articles that report herb-drug interactions, we can see that herb-drug interactions are often less systematically documented and less familiar to medical practitioners compared to drug-drug interactions. The nonstandardized naming of herbals with several confusing generic names together with an unfamiliar Latin name may make it difficult for medical professionals to anticipate and monitor herb-drug interaction [34]. Furthermore, most herbal formulas (especially traditional Chinese medicine, TCM) contain multiple herbs, making it often impossible to know which herbs and at what doses they are present.

In view of all the constraints of the existing literature, a comprehensive systematic review focusing on CBZ and overcoming the mentioned hurdles is warranted for healthcare professionals to make proper decisions. In this current report, we conducted a systematic review on interactions between CBZ and herbs, dietary supplements, and food, summarizing the scientific evidence for such interactions and providing recommendations for the combinational use. In addition to the usual databases (e.g., Medline and Embase), we also included several Chinese databases to identify reports of interactions between CBZ and TCM which are written in Chinese. The aim of this review is to provide a clear and systematic presentation of herb and food interactions with CBZ to alert and provide guidance for medical professionals when prescribing CBZ.

2. Materials and Methods

2.1. Data Sources and Literature Search

A computer-based search of the following English databases was conducted: AMED (1985–Oct. 2012), CINAHL Plus (1937–Oct. 2012), Cochrane Database of Systematic Reviews (2005–Dec. 2011), CENTRAL (Oct. 2012), Embase (1947–Oct. 2012), Medline (1946–Oct. 2012), and SciFinder Scholar (1907–Oct. 2012). The keyword search terms for carbamazepine (“Carbamazepine”, “Tegretol”, “Tegretol XR”, “G-32883”, “5H-Dibenz[b,f]azepine-5-carboxamide”) were combined, using the combination term AND, with a comprehensive list of keywords and MeSH search terms for herbs, food, and dietary supplements (Table 1). Such search list was refined to include most of the relevant articles. No language restriction was imposed during the search, but non-English articles were included only if they contained an English abstract with sufficient information. As defined by the Dietary Supplement Health and Education Act of 1994 (DSHEA), “dietary supplement” refers to any dietary products containing one or more of the following ingredients: vitamin, mineral, herb or other botanical, amino acid, and a dietary substance for use by man to supplement the diet by increasing the total dietary intake. In the current review, we separated “herb or other botanical” out and categorized this group as “herbs” while the remainings were referred to as “dietary supplement”. The third category is “food” which includes any specific traditional food/fruit products or beverages. Paper containing only a general term of “food” without specifying any particular food item will be excluded. In addition to the English databases, four Chinese databases had been searched, including Chinese BioMedical Literature Database (1978–Oct. 2012), China Journal Net (1915–Oct. 2012), Traditional Chinese Medical Database System (1984–Oct. 2012), and Chinese Medical Academic Conference Database (1994–Oct. 2012). The MeSH headings and keywords used for the search were carbamazepine (Chinese name, Chinese common names, and chemical names) in combination with the Chinese equivalent terms of “interaction”, “Chinese herbal medicines”, and “Chinese and Western medicines” (“jie he”, “xiang hu zuo yong”, and “zong yao”, “zong cao yao”, “zong xi yi”). The bibliographies of every retrieved article were checked for any additional pertinent studies.

2.2. Inclusion Criteria and Data Extraction

The selection of relevant reports and evaluation of article eligibility was carried out by two reviewers independently (Fong and Gao). Articles were considered eligible for evaluation if they contained original data involving herb, food, or dietary supplement interactions with CBZ without restriction for in vitro studies, animal studies, clinical studies observational studies, or review articles. Any discrepancies were resolved by a third author (Zuo). All relevant literature fulfilling our inclusion criteria were extracted and complied, except for the interacting pairs that have beneficial effects.

We grouped the natural products into four categories: TCM, other herb/botanical, vitamin/mineral/amino acid, and food. We categorized the mechanisms for pairs of interactions into three types: pharmacokinetics, pharmacodynamics, and both. In order to standardize the names of the included TCMs, the official compendium Pharmacopoeia of the People’s Republic of China 2010 (Chinese Pharmacopoeia) was consulted and their Latin names (for herbs) or Chinese pinyin names (for herbal formulae) were presented.

3. Results

3.1. Literature Search

A total of 3179 articles was initially found through database searches while an addition of 14 articles were obtained from scrutinizing the bibliographies of relevant literatures. 196 articles fulfilling the inclusion criteria were selected for further evaluation with perfect agreement between the two authors. Finally, seventy-four articles with full text, including 40 original articles and 34 review articles, were qualified to undergo an in-depth review (Figure 1); a total of 33 unique herbal products/dietary supplement/food-CBZ interacting pairs were identified from these articles. Summaries of the in vitro, animal, and clinical studies to retrieve information about interactions between CBZ and herbal products/dietary supplement/food for the original studies are listed in Tables 2 and 3, respectively. Among the original studies (), most are animal () and human () studies, with 2 mechanistic in vitro/ex vivo studies. Regarding the studied types of interaction, the majority () are pharmacokinetic interactions followed by both pharmacokinetic and pharmacodynamic interactions () and pharmacodynamic interactions ().

3.2. Interactions between Herbal Products and CBZ

Nineteen of the included original articles documented the interactions between 20 different herbal products and CBZ, where TCMs in the form of crude drug, extract, or single TCM compound were the major studied herbal products (). Among the 17 documented pharmacokinetic interactions between CBZ and TCMs, Cassia auriculata Linn., piperine (an active compound in Piper longum Linn.), Platycodonis Radix, and Polygonum cuspidatum were demonstrated to increase the plasma level/oral bioavailability of CBZ through decreasing the metabolism of CBZ or improving gastric solubility of CBZ [37, 47–49]. On the other hand, ginkgo biloba, Hu-gan-ning pian, Jia-wei-xiao-yao-san, and Xiao-yao-san decreased the plasma level/oral bioavailbaility of CBZ through increasing the metabolism of CBZ via CYP3A4 induction [40, 44, 53]. Ginsenoside (an active compound in ginseng) was also shown to activate CYP3A4 activity in vitro and thereby increased CBZ metabolism [39]. Xiao-qing-long-tang and Xiao-cha-hu-tang delayed the time for CBZ to reach peak plasma concentration through decreasing gastric emptying rate [38, 50], whereas Paeoniae Radix decreased the of CBZ through possibly improving dissolution of CBZ [46]. Acorus calamus Linn., berberine (an active compound in Coptidis rhizome), Cardiospermum halicacabum Linn., Chai-hu-jia-long-gu-mu-li-tang, and Hypericum perforatum Linn. did not alter the plasma levels or other pharmacokinetic parameters of CBZ in animal or human studies [35–38, 42]. As regards the pharmacodynamic interactions between CBZ and TCMs, there were three articles reporting the effect of TCMs on the efficacy and/or side effects of CBZ. Acorus calamus Linn. was shown to have an additive antiepileptic activity with CBZ in an animal study [35]. Xiao-yao-san might increase the incidence of dizziness, blurred vision, skin rash, and nausea when coadministered with CBZ in a clinical study [53] while Cardiospermum halicacabum Linn. and Cassia auriculata Linn. did not potentiate CBZ-related toxicity in rats [37]. The three remaining herbal products categorized as “other herb/botanical” that had documented herb-drug interactions with CBZ were Ispaghula husk, mentat, and septilin. Ispaghula husk, also more commonly known as psyllium, decreased the oral bioavailability and absorption of CBZ in four healthy volunteers [43] while septilin also decreased the absorption of CBZ in rabbits possibly through interfering with the gastric emptying or intestinal transit time [50]. On the contrary, mentat (BR 16A) increased the bioavailability of CBZ in rabbits through an unknown mechanism [45].

3.3. Interactions between Dietary Supplement/Food and CBZ

A total of twenty-one original literatures covering 13 different dietary supplement/food-CBZ interaction studies were recorded in the current review. These included beverages (), food substances (), and dietary supplements (). Alcohol did not affect the pharmacokinetics of CBZ in healthy volunteers but increased the oral bioavailability and decreased the metabolism of CBZ in alcoholics [55]. Alcohol-CBZ combination also had an additive neurotoxicity in animals [54]. Another beverage Coca-Cola increased the oral bioavailability of CBZ in a clinical study which may be due to the enhanced dissolution of CBZ by its acidity [60]. Caffeine decreased the oral bioavailability as well as the antiepileptic efficacy of CBZ in human and animal studies, respectively [57–59]. Four juices, namely, grapefruit juice, kinnow juice, pomegranate juice, and star fruit juice, were demonstrated to increase the oral bioavailability of CBZ through inhibiting enteric CYP3A4 activity [62, 66, 71, 74] though an ex vivo study suggested that pomegranate juice might induce enteric CYP3A4 due to the decreased intestinal permeation of CBZ [72]. Pharmacokinetic interactions between food substances and CBZ were recorded: butter increased while soy bean decreased the oral bioavailability of CBZ in animal study. The former might improve dissolution of CBZ while the later might decrease the gastric emptying and enhance the metabolism of CBZ [56, 73]. Although honey was shown to decrease the oral bioavailability of CBZ in rabbits, it had no effect on the pharmacokinetic parameters of CBZ in human [63–65]. As regards the dietary supplement-CBZ interactions, folinic acid did not alter the plasma level of CBZ in rats [61] while nicotinamide increased CBZ plasma level and decreased its clearance in two children with epilepsy [70]. Melatonin did not interact with CBZ pharmacokinetically but potentiated the antiepileptic activity of CBZ in both animal and human studies [67–69].

4. Discussion

Patients on antiepileptic therapy are usually on a long-term basis. Several antiepileptic drugs require therapeutic drug monitoring and are prone to drug interactions which may lead to serious consequences. CBZ is one of the antiepileptic drugs that are on the “watch-list”. With the increased popularity of herbal products as well as dietary supplement, prescribers may need to be aware of the potential herb-drug or food-drug interactions when prescribing and monitoring CBZ therapy. In this study, we had conducted a systematic review and summarized the up-to-date evidence of the interactions between CBZ and herbal products/food/dietary supplements that have been reported in primary literature.

In order to achieve a comprehensive literature search, a total of eleven databases were searched. These included two conventional databases (EMBASE and MEDLINE), five other English databases (AMED, CINAHL Plus, Cochrane Database of Systematic Reviews, CENTRAL, and SciFinder Scholar) four Chinese databases. We had also consulted some relative tertiary literatures including Stockley’s Herbal Medicines Interactions and Natural Medicines Comprehensive Database in case of any additional information. The keywords used for the search were optimized and refined in an attempt to include most of the relevant literatures (Table 1). We suggest that this search strategy could be applied on the search of other drugs—herb/food/dietary supplement interactions by substituting the drug name. It is interesting to note that, although a total of 100 clinical trials or case reports involving the concurrent use of TCMs with CBZ were identified from the Chinese databases, more than 90 of them focus on the beneficial effects or the antagonism of the side effects of CBZ of such combinational use and fallout from our inclusion criteria.

There were altogether 33 different herbal products/food/dietary supplements identified from literature in which their effects on CBZ were studied. These included 17 TCMs, 3 other herbs/botanicals, 10 foods, and 3 dietary supplements. The large number of studies involving TCM-drug interactions implies that TCM warrants special attention when coadministered with CBZ. However, the nonstandardized naming and multiple constituents of TCMs often confuse prescribers when anticipating such interaction. After extracting the herbal names from the original articles, we standardized the herbal names in Latin according to the Chinese Pharmacopoeia 2010 (Table 2). In order to raise the prescribers’ awareness to the different names of the TCM products, we also provide the synonyms of the included TCMs in Table 4. For herbal formulae, their composition and content were also listed (Table 5).

No fatal or severe interactions between CBZ and herbal products/food/dietary supplement were found from the literature search. Majority of the studied interactions were pharmacokinetic-based, where the oral bioavailability or plasma level of CBZ was significantly altered by the natural products (Table 6). Twelve natural products/food, elevated the oral bioavailability/plasma level of CBZ with six of them demonstrating clinical evidence, namely, piperine, alcohol, Coca-Cola, grapefruit juice, kinnow juice, and nicotinamide (highlighted in bold in Table 6). In most cases the authors suggested that the increase in plasma CBZ concentrations was due to the inhibition of CYP3A4-mediated metabolism of CBZ by these natural products. Since CBZ has a narrow therapeutic index, and the side effects of CBZ are concentration-dependent, the increment of CBZ plasma level may result in serious adverse effects such as diplopia and nystagmus [75]. Therefore, it is advised to avoid the consumption of the food/herbal products which could elevate the CBZ plasma level as listed in Table 6.

On the other hand, nine natural products diminished the oral bioavailability/plasma level of CBZ significantly with four of them having clinical evidences: Ispaghula husk, Xiao-yao-san, Jia-wei-xiao-yao san, and caffeine (Table 4). Multiple mechanisms may contribute to the decrease of CBZ plasma level by these natural products, one of which is the increase in the metabolism of CBZ by induction of CYP3A4 (by Jia-wei-xiao-yao-san, ginkgo biloba, and soybean) and mixed function oxidase (by caffeine) activity. Ispaghula husk, septilin, soybean and Xiao-cha-hu-tang reduced the plasma level of CBZ by affecting its gastric absorption. Coadministration of CBZ with herbal products/food which are enzyme inducers entails the possibility of a clinically significant drug interaction. The reduction of CBZ plasma level may imply that less CBZ is present in the target site to assert its antiepileptic activity; a worsened seizure control may follow unless the dosage of CBZ is adjusted accordingly [76]. Since enzyme induction is a reversible phenomenon, particular caution is required when an enzyme-inducing agent is discontinued because the serum concentration of concurrently administered CBZ may rebound to potentially toxic levels. Patients are therefore not recommended to take the food/herbal products which could decrease the CBZ plasma level listed in Table 6.

Furthermore, CBZ has poor water solubility; consequently, its absorption time and extent are thus easily affected by coadministration of substances that may alter gastric conditions. For example, Xiao-cha-hu-tang and Xiao-qing-long-tang delayed the time for CBZ to reach peak plasma concentration by decreasing the gastric emptying rate. By improving the dissolution of CBZ, Paeoniae Radix allowed faster absorption while butter and Platycodonis Radix increased the extent absorption of CBZ.

Any changes of the plasma level of CBZ-10,11 epoxide caused by the simultaneous administration of herbal products/food/dietary supplements with CBZ should also be noted. Formed through the CYP3A4-mediated metabolism in intestine and liver, CBZ-10,11 epoxide is the principle metabolite of CBZ which is pharmacologically active and may contribute to the toxicities of CBZ [77]. Neurotoxic symptoms including ataxia, dizziness, nausea, and diplopia had been observed in patients in which lamotrigine or loxapine was added to CBZ therapy, with elevated blood levels of CBZ-10,11-epoxide [78, 79]. Polygonum cuspidatum, a widely used TCM indicated for menstrual and postpartum difficulties, traumatic burns, and acute viral hepatitis, was shown to increase CBZ and CBZ-10,11-epoxide levels in plasma, brain, liver, and kidney in an animal study [49]. On the other hand, Xiao-cha-hu-tang decreased the oral bioavailability of CBZ-10,11-epoxide in rats [51]. Although there was no clinical evidences of these two TCMs causing an elevated/decreased plasma level of CBZ-10,11-epoxide or showing their linkage to pharmacodynamic outcome, it is rational to pay necessary cautions and avoid their combinational use with CBZ.

Compared to pharmacokinetic interactions, there were fewer studies reporting pharmacodynamic-based interactions between herbal products/food/dietary supplements and CBZ. Pharmacodynamic interaction refers to the alteration of efficacy (antiepileptic activity) and/or the adverse effects of CBZ in the presence of natural products. Melatonin and Acorus calamus Linn. potentiated the anticonvulsant activity of CBZ but had no effect on the plasma levels of CBZ in animal studies so such interactions are mainly pharmacodynamic-based. Despite the apparent efficacy-boosting effect, it is best to avoid the use of melatonin or Acorus calamus Linn. with CBZ until there further clinical evidence on the safe usage of such combination. Caffeine, on the other hand, decreased the plasma level of CBZ in human while decreased the antiepileptic efficacy of CBZ in mouse. Although there are no clinical studies on whether the antiepileptic activity of CBZ is influenced by caffeine, advice should be given to patients on CBZ therapy not to take caffeine. Caution should also be paid for beverage containing alcohol. Alcohol was demonstrated to have additive neurotoxicity with CBZ in mouse, including a potentiated motor incoordination and loss of righting reflex. Together with the fact that alcohol caused an increase in the oral bioavailability of CBZ in alcoholics, it is advised not to consume any alcohol while patients take CBZ. In a randomized double-blinded control trial, Xiao-yao-san increased the incidence of CBZ-related side effects including dizziness, blurred vision, skin rash, and nausea in patients with major depression or bipolar disorder. Though the mechanism is unknown, patients should be warned about the potential risks when taking this TCM with CBZ.

In this study, the documented evidence of interactions between CBZ and herbal products/food/dietary supplements was systematically reviewed from the published literature. The intention of this review was to provide guidance to assist healthcare professionals in identifying patients taking CBZ that are more susceptible to these interactions and make proper actions. A total of 33 unique herbal products/dietary supplement/food-CBZ interacting pairs were identified from this review. Considering the popularity and frequent usage of both CBZ (as first-line epilepsy regimen) and herbal products/food/dietary supplements, the number of studied interactions is considerably small. More evidence and reports are needed from research studies and, preferably, from adverse report system in clinical setting. Of course, the importance of therapeutic drug monitoring of CBZ is again emphasized while most pairs of natural products-CBZ interactions remained unknown. On the other hand, the amount of documented CBZ-herbal products/food/dietary supplements interactions might be underreported in this review due to several limitations, including publication bias and language restrictions. We had attempted to reduce language bias by including four evidence-based Chinese databases. However, the evidence regarding complementary alternative medicine or folk therapies, which were published in other languages (e.g., Japanese, Indian, and French), might be missing. Another limitation of this review was that it included all relevant information identified in the literature, regardless of the evidence types or quality of the studies. Such arrangement aimed to gather as much useful information regarding studies on interactions between CBZ and the natural products. Although species differences existed, human pharmacokinetic parameters and pharmacodynamic behavior could be successfully extrapolated from animal studies [80, 81]. Therefore, the data from animal studies are considered to be valuable, and hence the results should not be neglected.

5. Conclusion

This review provides a structured summary of the evidence of the documented interactions between CBZ and herbal products/food/dietary supplements. These findings should be helpful for healthcare professionals to identify potential herb-drug and food-drug interactions while prescribing CBZ and would also facilitate them to communicate these documented interactions to their patients, thus preventing potential adverse events and improving patients’ therapeutic outcomes.

Acknowledgment

Grant from Hospital Authority of Hong Kong (Reference no. L/M (Q08-040) to HAHO(S)/P/45).

References

N. F. Moran, K. Poole, G. Bell et al., “Epilepsy in the United Kingdom: seizure frequency and severity, anti-epileptic drug utilization and impact on life in 1652 people with epilepsy,” Seizure, vol. 13, no. 6, pp. 425–433, 2004.
View at: Publisher Site | Google Scholar
L. P. Hsieh and C. Y. Huang, “Antiepileptic drug utilization in Taiwan: analysis of prescription using national health insurance database,” Epilepsy Research, vol. 84, no. 1, pp. 21–27, 2009.
View at: Publisher Site | Google Scholar
I. Bielen, A. Sruk, M. Planjar-Prvan et al., “Age-related pattern of the antiepileptic drug utilization in active epilepsy: a population-based survey,” Collegium Antropologicum, vol. 33, no. 2, pp. 659–663, 2009.
View at: Google Scholar
L. Ishihara-Paul, D. J. Webb, M. Irizarry, and J. Weil, “Exploring differential prescribing between anti-epileptic drugs in epilepsy patients with a history of mood disorders,” Pharmacoepidemiology and Drug Safety, vol. 19, no. 3, pp. 289–295, 2010.
View at: Publisher Site | Google Scholar
D. Lowenstein, “Seizures and epilepsy,” in Harrison's Principle of Internal Medicine, E. Braunwald, S. Hauser, A. S. Fauci, D. H. Longo, and D. L. Kasper, Eds., pp. 2359–2369, McGraw-Hill Medical Publishing, New Delhi, India, 2005.
View at: Google Scholar
E. Barry and R. G. William, “Epilepsy,” in Pharmacotherapy: A Pathophysiologic Approach, J. T. DiPiro, R. Talbert, C. G. Yee, G. R. Matzke, G. B. Wells, and L. M. Posey, Eds., pp. 1023–1074, McGraw-Hill Medical Publishing, New Delhi, India, 2006.
View at: Google Scholar
T. A. Ketter, R. M. Post, and K. Worthington, “Principles of clinically important drug interactions with carbamazepine. Part I,” Journal of Clinical Psychopharmacology, vol. 11, no. 3, pp. 198–203, 1991.
View at: Google Scholar
G. C. Kane and J. J. Lipsky, “Drug-grapefruit juice interactions,” Mayo Clinic Proceedings, vol. 75, no. 9, pp. 933–942, 2000.
View at: Google Scholar
J. M. Potter and A. Donnelly, “Carbamazepine-10,11-epoxide in therapeutic drug monitoring,” Therapeutic Drug Monitoring, vol. 20, no. 6, pp. 652–657, 1998.
View at: Publisher Site | Google Scholar
E. L. So, K. H. Ruggles, G. D. Cascino, P. A. Ahmann, and K. W. Weatherford, “Seizure exacerbation and status epilepticus related to carbamazepine-10,11-epoxide,” Annals of Neurology, vol. 35, no. 6, pp. 743–746, 1994.
View at: Publisher Site | Google Scholar
M. Bialer, R. H. Levy, and E. Perucca, “Does carbamazepine have a narrow therapeutic plasma concentration range?” Therapeutic Drug Monitoring, vol. 20, no. 1, pp. 56–59, 1998.
View at: Publisher Site | Google Scholar
M. C. Bissery, P. Vrignaud, F. Lavelle, and G. G. Chabot, “Preclinical antitumor activity and pharmacokinetics of irinotecan (CPT-11) in tumor-bearing mice,” Annals of the New York Academy of Sciences, vol. 803, pp. 173–180, 1996.
View at: Publisher Site | Google Scholar
J. M. Pellock, “Carbamazepine side effects in children and adults,” Epilepsia, vol. 28, no. 3, pp. S64–S70, 1987.
View at: Google Scholar
R. S. Fisher and B. Cysyk, “A fatal overdose of carbamazepine: case report and review of literature,” Journal of Toxicology—Clinical Toxicology, vol. 26, no. 7, pp. 477–486, 1988.
View at: Google Scholar
L. Durelli, U. Massazza, and R. Cavallo, “Carbamazepine toxicity and poisoning: incidence, clinical features and management,” Medical Toxicology and Adverse Drug Experience, vol. 4, no. 2, pp. 95–107, 1989.
View at: Google Scholar
M. Vietri, A. Pietrabissa, F. Mosca, and G. M. Pacifici, “Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney,” European Journal of Clinical Pharmacology, vol. 56, no. 9-10, pp. 659–664, 2000.
View at: Publisher Site | Google Scholar
R. Herber, J. Magdalou, M. Haumont, R. Bidault, H. van Es, and G. Siest, “Glucuronidation of 3′-azido-3′-deoxythymidine in human liver microsomes: enzyme inhibition by drugs and steroid hormones,” Biochimica et Biophysica Acta, vol. 1139, no. 1-2, pp. 20–24, 1992.
View at: Publisher Site | Google Scholar
J. O. Miners and K. J. Lillywhite, “Assessment of the drug inhibitor specificity of the human liver 4-methylumbelliferone UDP-glucuronosyltransferase activity,” Biochemical Pharmacology, vol. 41, no. 5, pp. 838–841, 1991.
View at: Publisher Site | Google Scholar
N. Kaneda, H. Nagata, T. Furuta, and T. Yokokura, “Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse,” Cancer Research, vol. 50, no. 6, pp. 1715–1720, 1990.
View at: Google Scholar
D. D. Von Hoff, H. A. Burris III, J. Eckardt et al., “Preclinical and phase I trials of topoisomerase I inhibitors,” Cancer Chemotherapy and Pharmacology, vol. 34, supplement, pp. S41–S45, 1994.
View at: Google Scholar
M. F. Mohamed and R. F. Frye, “Effects of herbal supplements on drug glucuronidation. Review of clinical, animal, and in vitro studies,” Planta Medica, vol. 77, no. 4, pp. 311–321, 2011.
View at: Publisher Site | Google Scholar
L. C. Chen, Y. F. Chen, L. L. Yang, M. H. Chou, and M. F. Lin, “Drug utilization pattern of antiepileptic drugs and traditional Chinese medicines in a general hospital in Taiwan—a pharmaco-epidemiologic study,” Journal of Clinical Pharmacy and Therapeutics, vol. 25, no. 2, pp. 125–129, 2000.
View at: Publisher Site | Google Scholar
K. Easterford, P. Clough, S. Comish, L. Lawton, and S. Duncan, “The use of complementary medicines and alternative practitioners in a cohort of patients with epilepsy,” Epilepsy and Behavior, vol. 6, no. 1, pp. 59–62, 2005.
View at: Publisher Site | Google Scholar
K. Liow, E. Ablah, J. C. Nguyen et al., “Pattern and frequency of use of complementary and alternative medicine among patients with epilepsy in the midwestern United States,” Epilepsy and Behavior, vol. 10, no. 4, pp. 576–582, 2007.
View at: Publisher Site | Google Scholar
D. Bhalla, K. Chea, C. Hun et al., “Population-based study of epilepsy in Cambodia associated factors, measures of impact, stigma, quality of life, knowledge-attitude-practice, and treatment gap,” PLoS ONE, vol. 7, no. 10, Article ID e46296, 2012.
View at: Publisher Site | Google Scholar
M. Tandon, S. Prabhakar, and P. Pandhi, “Pattern of use of complementary/alternative medicine (CAM) in epileptic patients in a tertiary care hospital in India,” Pharmacoepidemiology and Drug Safety, vol. 11, no. 6, pp. 457–463, 2002.
View at: Publisher Site | Google Scholar
M. A. Danesi and J. B. Adetunji, “Use of alternative medicine by patients with epilepsy: a survey of 265 epileptic patients in a developing country,” Epilepsia, vol. 35, no. 2, pp. 344–351, 1994.
View at: Google Scholar
S. D. White, “Deciphering “integrated Chinese and Western medicine” in the rural Lijiang basin: state policy and local practice(s) in socialist China,” Social Science and Medicine, vol. 49, no. 10, pp. 1333–1347, 1999.
View at: Publisher Site | Google Scholar
N. Howard, C. Tsourounis, and J. Kapusnik-Uner, “Dietary supplement survey of pharmacists: personal and professional practices,” Journal of Alternative and Complementary Medicine, vol. 7, no. 6, pp. 667–680, 2001.
View at: Google Scholar
C. Ioannides, “Pharmacokinetic interactions between herbal remedies and medicinal drugs,” Xenobiotica, vol. 32, no. 6, pp. 451–478, 2002.
View at: Publisher Site | Google Scholar
Z. Hu, X. Yang, P. C. L. Ho et al., “Herb-drug interactions: a literature review,” Drugs, vol. 65, no. 9, pp. 1239–1282, 2005.
View at: Publisher Site | Google Scholar
H. H. Tsai, H. W. Lin, A. S. Pickard, H. Y. Tsai, and G. B. Mahady, “Evaluation of documented drug interactions and contraindications associated with herbs and dietary supplements: a systematic literature review,” International Journal of Clinical Practice, vol. 66, no. 11, pp. 1056–1078, 2012.
View at: Publisher Site | Google Scholar
E. Mills, P. Wu, B. C. Johnston, K. Gallicano, M. Clarke, and G. Guyatt, “Natural health product-drug interactions: a systematic review of clinical trials,” Therapeutic Drug Monitoring, vol. 27, no. 5, pp. 549–557, 2005.
View at: Publisher Site | Google Scholar
N. Samuels, Y. Finkelstein, S. R. Singer, and M. Oberbaum, “Herbal medicine and epilepsy: proconvulsive effects and interactions with antiepileptic drugs,” Epilepsia, vol. 49, no. 3, pp. 373–380, 2008.
View at: Publisher Site | Google Scholar
J. Katyal, V. Sarangal, and Y. K. Gupta, “Interaction of hydroalcoholic extract of Acorus calamus Linn. with sodium valproate and carbamazepine,” Indian Journal of Experimental Biology, vol. 50, no. 1, pp. 51–55, 2012.
View at: Google Scholar
W. Qiu, X. H. Jiang, C. X. Liu, Y. Ju, and J. X. Jin, “Effect of berberine on the pharmacokinetics of substrates of CYP3A and P-gp,” Phytotherapy Research, vol. 23, no. 11, pp. 1553–1558, 2009.
View at: Publisher Site | Google Scholar
I. Thabrew, J. Munasinghe, S. Chackrewarthi, and S. Senarath, “The effects of Cassia auriculata and Cardiospermum halicacabum teas on the steady state blood level and toxicity of carbamazepine,” Journal of Ethnopharmacology, vol. 90, no. 1, pp. 145–150, 2004.
View at: Publisher Site | Google Scholar
N. Ohnishi, S. Nakasako, K. Okada et al., “Studies on interactions between traditional herbal and western medicines. IV: lack of pharmacokinetic interactions between saiko-ka-ryukotsu-borei-to and carbamazepine in rats,” European Journal of Drug Metabolism and Pharmacokinetics, vol. 26, no. 1-2, pp. 129–135, 2001.
View at: Google Scholar
M. Haop, Y. Zhao, P. Chen et al., “Structure-activity relationship and substrate-depedent phenomena in effects of ginsenosides on activities of drug-metabolizing P450 enzymes,” PLoS ONE, vol. 3, no. 7, Article ID e2697, 2008.
View at: Publisher Site | Google Scholar
R. H. Chandra, M. Rajkumar, and C. Veeresham, “Pharmacokinetic interaction of ginkgo biloba with carbamazepine,” Planta Medica, no. 4, p. 454, 2009, Proceedings of the 8th Annual Oxford International Conference on the Science of Botanicals University.
View at: Google Scholar
Y. Zheng, C. Q. Yang, and C. H. Zhang, “Effect of huganning tablets on pharmacokinetics of carbamazepine in rats,” Chinese Journal of Pharmaceuticals, vol. 40, no. 2, pp. 117–119, 2009.
View at: Google Scholar
A. H. Burstein, R. L. Horton, T. Dunn, R. M. Alfaro, S. C. Piscitelli, and W. Theodore, “Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers,” Clinical Pharmacology and Therapeutics, vol. 68, no. 6, pp. 605–612, 2000.
View at: Publisher Site | Google Scholar
M. A. Etman, “Effect of a bulk forming laxative on the bioavailability of carbamazepine in man,” Drug Development and Industrial Pharmacy, vol. 21, no. 16, pp. 1901–1906, 1995.
View at: Google Scholar
Z. J. Zhang, W. H. Kang, Q. Li, and Q. Tan, “The beneficial effects of the herbal medicine free and easy wanderer plus (FEWP) for mood disorders: double-blind, placebo-controlled studies,” Journal of Psychiatric Research, vol. 41, no. 10, pp. 828–836, 2007.
View at: Publisher Site | Google Scholar
M. Tripathi, R. Sundaram, M. Rafiq, M. V. Venkataranganna, S. Gopumadhavan, and S. K. Mitra, “Pharmacokinetic interactions of Mentat with carbamazepine and phenytoin,” European Journal of Drug Metabolism and Pharmacokinetics, vol. 25, no. 3-4, pp. 223–226, 2000.
View at: Google Scholar
L. C. Chen, Y. F. Chen, M. H. Chou, M. Lin, L. Yang, and K. Yen, “Pharmacokinetic interactions between carbamazepine and the traditional Chinese medicine Paeoniae Radix,” Biological and Pharmaceutical Bulletin, vol. 25, no. 4, pp. 532–535, 2002.
View at: Publisher Site | Google Scholar
S. Pattanaik, D. Hota, S. Prabhakar, P. Kharbanda, and P. Pandhi, “Pharmacokinetic interaction of single dose of piperine with steady-state carbamazepine in epilepsy patients,” Phytotherapy Research, vol. 23, no. 9, pp. 1281–1286, 2009.
View at: Publisher Site | Google Scholar
P. Liu and L. Wei, “Effect of Platycodon grandiflorum on the blood concentration of carbamazepine in rabbits,” Evaluation and Analysis of Drug-Use in Hospitals of China, vol. 8, no. 5, 2008.
View at: Google Scholar
Y. C. Chi, S. P. Lin, and Y. C. Hou, “A new herb-drug interaction of Polygonum cuspidatum, a resveratrol-rich nutraceutical, with carbamazepine in rats,” Toxicology and Applied Pharmacology, vol. 263, no. 3, pp. 315–322, 2012.
View at: Publisher Site | Google Scholar
S. K. Garg, A. S. Islam, and N. Kumar, “Effect of septilin—a herbal preparation on pharmacokinetics of carbamazepine in rabbits,” Indian Journal of Physiology and Pharmacology, vol. 42, no. 4, pp. 527–532, 1998.
View at: Google Scholar
N. Ohnishi, K. Okada, M. Yoshioka et al., “Studies on interactions between traditional herbal and western medicines. V. Effects of Sho-saiko-to (Xiao-Cai-hu-Tang) on the pharmacokinetics of carbamazepine in rats,” Biological and Pharmaceutical Bulletin, vol. 25, no. 11, pp. 1461–1466, 2002.
View at: Publisher Site | Google Scholar
N. Ohnishi, Y. Yonekawa, S. Nakasako et al., “Studies on interactions between traditional herbal and western medicines. I. Effects of Sho-seiryu-to on the pharmacokinetics of carbamazepine in rats,” Biological and Pharmaceutical Bulletin, vol. 22, no. 5, pp. 527–531, 1999.
View at: Google Scholar
W. K. Q. Li, Q. Tan, Z. Zhang et al., “Randomized double-blind controlled clinical trial of the combination of Xiao-yao-san and carbamazepine in the treatment of bipolar disorders,” Zhong Guo Lin Chuang Yao Li Xue Za Zhi, vol. 21, pp. 336–340, 2005.
View at: Google Scholar
M. S. Dar, M. Hardee, and T. Ganey, “Brain adenosine modulation of behavioral interactions between ethanol and carbamazepine in mice,” Alcohol, vol. 6, no. 4, pp. 297–301, 1989.
View at: Google Scholar
B. Sternebring, A. Lidén, K. Andersson, and A. Melander, “Carbamazepine kinetics and adverse effects during and after ethanol exposure in alcoholics and in healthy volunteers,” European Journal of Clinical Pharmacology, vol. 43, no. 4, pp. 393–397, 1992.
View at: Publisher Site | Google Scholar
S. Sidhu, S. Malhotra, and S. K. Garg, “Influence of high fat diet (butter) on the pharmacokinetics of phenytoin and carbamazepine,” Methods and Findings in Experimental and Clinical Pharmacology, vol. 26, no. 8, pp. 635–638, 2004.
View at: Google Scholar
J. Vaz, C. Kulkarni, J. David, and T. Joseph, “Influence of caffeine on pharmacokinetic profile of sodium valproate and carbamazepine in normal human volunteers,” Indian Journal of Experimental Biology, vol. 36, no. 1, pp. 112–114, 1998.
View at: Google Scholar
S. J. Czuczwar, M. Gasior, W. Janusz, B. Szczepanik, D. Wlodarczyk, and Z. Kleinrok, “Influence of different methylxanthines on the anticonvulsant action of common antiepileptic drugs in mice,” Epilepsia, vol. 31, no. 3, pp. 318–323, 1990.
View at: Google Scholar
M. Gasior, K. Borowicz, Z. X. Kleinrok, and S. J. Czuczwar, “Chronic caffeine and the anticonvulsant potency of antiepileptic drugs against maximal electroshock,” Pharmacology Biochemistry and Behavior, vol. 54, no. 4, pp. 639–644, 1996.
View at: Publisher Site | Google Scholar
S. Malhotra, R. K. Dixit, and S. K. Garg, “Effect of an acidic beverage (Coca-Cola) on the pharmacokinetics of carbamazepine in healthy volunteers,” Methods and Findings in Experimental and Clinical Pharmacology, vol. 24, no. 1, pp. 31–33, 2002.
View at: Publisher Site | Google Scholar
D. B. Smith and G. F. Carl, “Interactions between folates and carbamazepine or valproate in the rat,” Neurology, vol. 32, no. 9, pp. 965–969, 1982.
View at: Google Scholar
S. K. Garg, N. Kumar, V. K. Bhargava, and S. K. Prabhakar, “Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy,” Clinical Pharmacology and Therapeutics, vol. 64, no. 3, pp. 286–288, 1998.
View at: Publisher Site | Google Scholar
K. Koumaravelou, C. Adithan, C. H. Shashindran, M. Asad, and B. K. Abraham, “Effect of honey on carbamazepine kinetics in rabbits,” Indian Journal of Experimental Biology, vol. 40, no. 5, pp. 560–563, 2002.
View at: Google Scholar
S. Malhotra, S. K. Garg, and R. K. Dixit, “Effect of concomitantly administered honey on the pharmacokinetics of carbamazepine in healthy volunteers,” Methods and Findings in Experimental and Clinical Pharmacology, vol. 25, no. 7, pp. 537–540, 2003.
View at: Publisher Site | Google Scholar
V. Thomas, K. Ramasamy, R. Sundaram, and A. Chandrasekaran, “Effect of honey on CYP3A4 enzyme and P-glycoprotein activity in healthy human volunteers,” Iranian Journal of Pharmacology and Therapeutics, vol. 6, no. 2, pp. 171–176, 2007.
View at: Google Scholar
S. K. Garg, V. K. Bhargava, H. James, N. Kumar, and S. Prabhakar, “Influence of kinnow juice on the bioavailability of carbamazepine in healthy male volunteers,” Neurology India, vol. 46, no. 3, pp. 229–231, 1998.
View at: Google Scholar
K. K. Borowicz, R. Kamiński, M. Gasior, Z. Kleinrok, and S. J. Czuczwar, “Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice,” European Neuropsychopharmacology, vol. 9, no. 3, pp. 185–190, 1999.
View at: Publisher Site | Google Scholar
M. Gupta, Y. K. Gupta, S. Agarwal, S. Aneja, M. Kalaivani, and K. Kohli, “Effects of add-on melatonin administration on antioxidant enzymes in children with epilepsy taking carbamazepine monotherapy: a randomized, double-blind, placebo-controlled trial,” Epilepsia, vol. 45, no. 12, pp. 1636–1639, 2004.
View at: Publisher Site | Google Scholar
Y. K. Gupta, M. Gupta, G. Chaudhary, and K. Kohli, “Modulation of antiepileptic effect of phenytoin and carbamazepine by melatonin in mice,” Methods and Findings in Experimental and Clinical Pharmacology, vol. 26, no. 2, pp. 99–102, 2004.
View at: Publisher Site | Google Scholar
H. M. Said, R. Redha, and W. Nylander, “Biotin transport in the human intestine: inhibition by anticonvulsant drugs,” The American Journal of Clinical Nutrition, vol. 49, no. 1, pp. 127–131, 1989.
View at: Google Scholar
M. Hidaka, M. Okumura, K. Fujita et al., “Effects of pomegranate juice on human cytochrome P450 3A (CYP3A) and carbamazepine pharmacokinetics in rats,” Drug Metabolism and Disposition, vol. 33, no. 5, pp. 644–648, 2005.
View at: Publisher Site | Google Scholar
D. Adukondalu, Y. S. Kumar, Y. V. Vishnu, R. S. Kumar, and Y. M. Rao, “Effect of pomegranate juice pre-treatment on the transport of carbamazepine across rat intestine,” DARU, Journal of Pharmaceutical Sciences, vol. 18, no. 4, pp. 254–259, 2010.
View at: Google Scholar
D. Singh and M. Asad, “Effect of soybean administration on the pharmacokinetics of carbamazepine and omeprazole in rats,” Fundamental and Clinical Pharmacology, vol. 24, no. 3, pp. 351–355, 2010.
View at: Publisher Site | Google Scholar
M. Hidaka, M. Okumura, T. Ogikubo et al., “Transient inhibition of CYP3A in rats by star fruit juice,” Drug Metabolism and Disposition, vol. 34, no. 3, pp. 343–345, 2006.
View at: Publisher Site | Google Scholar
E. Spina, F. Pisani, and E. Perucca, “Clinically significant pharmacokinetic drug interactions with carbamazepine,” Clinical Pharmacokinetics, vol. 31, no. 3, pp. 198–214, 1996.
View at: Google Scholar
E. Perucca, “Clinically relevant drug interactions with antiepileptic drugs,” The British Journal of Clinical Pharmacology, vol. 61, no. 3, pp. 246–255, 2006.
View at: Publisher Site | Google Scholar
Y. C. Wong, S. Qian, and Z. Zuo, “Regioselective biotransformation of CNS drugs and its clinical impact on adverse drug reactions,” Expert Opinion on Drug Metabolism and Toxicology, vol. 8, no. 7, pp. 833–854, 2012.
View at: Publisher Site | Google Scholar
T. Warner, P. N. Patsalos, M. Prevett, A. A. Elyas, and J. S. Duncan, “Lamotrigine-induced carbamazepine toxicity: an interaction with carbamazepine-10,11-epoxide,” Epilepsy Research, vol. 11, no. 2, pp. 147–150, 1992.
View at: Publisher Site | Google Scholar
M. E. Pitterle and D. M. Collins, “Carbamazepine-10-11-epoxide evaluation associated with coadministration of loxapine or amoxapine,” Epilepsia, vol. 29, article 654, 1988.
View at: Google Scholar
L. J. Jolivette and K. W. Ward, “Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: molecular properties associated with extrapolative success or failure,” Journal of Pharmaceutical Sciences, vol. 94, no. 7, pp. 1467–1483, 2005.
View at: Publisher Site | Google Scholar
F. Vocci and T. Farber, “Extrapolation of animal toxicity data to man,” Regulatory Toxicology and Pharmacology, vol. 8, no. 4, pp. 389–398, 1988.
View at: Google Scholar

Copyright

Copyright © 2013 Sophia Yui Kau Fong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

22171

Downloads

3003

Citations